SCHEMBL6475901

SCHEMBL6475901

CCOC(=O)C(Cc1ccc(OCCCn2c(=O)sc3ccccc32)cc1)C(=O)OCC

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.66
CYP3A4 P08684 3/20 0.66
CYP2D6 P10635 3/20 0.66
CYP2C19 P33261 3/20 0.66
TDP1 Q9NUW8 2/20 0.66
HPGD P15428 1/20 0.66
RAB9A P51151 8/20 0.61
NPC1 O15118 7/20 0.61
SMN1; SMN2 Q16637 7/20 0.61
CYP1A2 P05177 2/20 0.61
CYP2C9 P11712 2/20 0.61
TP53 P04637 2/20 0.58
PPARG P37231 5/20 0.57
LMNA P02545 1/20 0.55
ATM Q13315 1/20 0.54
TSHR P16473 3/20 0.54
ALDH1A1 P00352 2/20 0.54
MAPK1 P28482 2/20 0.54
PPARA Q07869 5/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6476253 0.95 NPC1 (0.65) L3MBTL1CYP3A4CYP2D6CYP2C19TDP1
SCHEMBL6476972 0.91 NPC1 (0.63) L3MBTL1CYP3A4CYP2D6CYP2C19TDP1
SCHEMBL6486368 0.89 RAB9A (0.72) L3MBTL1CYP3A4CYP2D6CYP2C19TDP1
SCHEMBL6488473 0.86 PPARG (0.75) L3MBTL1CYP3A4CYP2D6CYP2C19TDP1
SCHEMBL6476961 0.84 PPARG (0.60) L3MBTL1CYP3A4CYP2D6CYP2C19TDP1
SCHEMBL6484845 0.83 RAB9A (0.71) L3MBTL1CYP3A4CYP2D6CYP2C19TDP1
SCHEMBL6475685 0.82 PPARG (0.73) L3MBTL1CYP3A4CYP2D6CYP2C19TDP1
SCHEMBL6476966 0.81 PPARG (0.59) L3MBTL1CYP3A4CYP2D6CYP2C19TDP1
SCHEMBL6486022 0.80 PPARG (0.67) L3MBTL1CYP3A4CYP2D6CYP2C19TDP1
SCHEMBL6477610 0.79 L3MBTL1 (0.65) L3MBTL1CYP3A4CYP2D6CYP2C19TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919362-B2 Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2005-07-19 US disclosed
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2003-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same CYP2F1, CYP11B2, CYP4B1 L3MBTL1 4870/4885CYP3A4 17/4885CYP2D6 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.